Ryan Scott

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Michael R. Grunwald, MD, discusses findings from a real-world observational study of risk factors related to disease progression in polycythemia vera.

Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.

Adam C. Berger, MD, FACS, discusses key messages for oncologists during Sarcoma Awareness Month.